You are here: Industry Insights > Saphnelo

News List

EMA’s CHMP recommends approval for AstraZeneca’s Saphnelo to treat SLE Pharmaceutical-Business-Review
December 22, 2021
A fully human monoclonal antibody, Saphnelo targets subunit 1 of the type one interferon (type 1 IFN) receptor, blocking the type 1 IFN’s activity.
Saphnelo Recommended for Approval in the EU by CHMP for the Treatment of Patients with Systemic Lupus Erythematosus AmericanPharmaceuticalReview
December 21, 2021
AstraZeneca’s Saphnelo (anifrolumab) has been recommended for marketing authorization in the European Union (EU) as an add-on therapy for the treatment of adult patients with moderate to severe...
CHMP recommend Saphnelo for systematic lupus erythematosus pharmatimes
December 21, 2021
With approval, Saphnelo would be the first available treatment for systematic lupus erythematosus in Europe in over ten years.
Saphnelo Approved in US for Moderate to Severe Systemic Lupus Erythematosus americanpharmaceuticalreview
August 04, 2021
AstraZeneca’s Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.
AZ’s Saphnelo scores US approval for systemic lupus erythematosus pharmatimes
August 03, 2021
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Saphnelo (anifrolumab) for the treatment of moderate to severe systemic lupus erythematosus (SLE).
FDA Approves Saphnelo (anifrolumab) for Moderate to Severe Systemic Lupus Erythematosus drugs
August 03, 2021
AstraZeneca’s Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.